Background: Cervical cancer treatment options are limited for patients with recurrent and/or metastatic cervical cancer. Tisotumab vedotin (TV) is an antibody-drug conjugate (ADC) composed of a human antibody targeted to tissue factor (TF), a protease-cleavable linker and the potent microtubule-disrupting agent monomethyl auristatin E (MMAE). The phase 1/2 GEN701 trial (NCT02001623) initially enrolled 34 patients with recurrent or metastatic cervical cancer in the cervical expansion cohort. Treatment with intravenous TV at 2 mg/kg every 3 weeks resulted in an overall response rate of 32% (confirmed and unconfirmed responses) by investigator review per RECIST v1.1 as a part of preliminary analysis. Furthermore, TV was safe and tolerable with a safety profile generally consistent with other MMAE-based ADCs Methods: This is an international, multicenter, open-label, non-randomized phase 2 trial evaluating efficacy of TV in approximately 100 patients with recurrent and/or metastatic cervical cancer who have progressed on a standard 1^st line therapy and who have not received more than 2 prior systemic treatment regimens for recurrent or metastatic disease. Response will be assessed every 6 weeks for the first 30 weeks, and then every 12 weeks thereafter. The primary objective is to assess the confirmed objective response rate (ORR) by an independent review committee (IRC) using RECIST v1.1. Secondary efficacy endpoints include: duration of response (DOR), ORR by investigator review, time to response (TTR), progression free survival (PFS), overall survival (OS), and safety and tolerability. For the ORR analyses, a 2-sided 95% exact confidence interval will be calculated using the Clopper-Pearson method. PFA and OS will be analyzed using the Kaplan-Meier method. Adverse events (AEs) will be monitored and graded using CTCAE v5.0.